Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
New to Comunitee?

or Sign Up with Email



JAN 30, 2013 - Yahoo! News

A Must Read - Share

Sanofi expects FDA decision on Lemtrada in H2

PARIS (Reuters) - Sanofi expects the U.S. Food and Drug Administration to rule on its application for multiple sclerosis treatment Lemtrada by the second half of this year. The injectable drug, chemically known as alemtuzumab, is one of the new products the French drug maker is betting on to restore growth after losing several blockbusters to generic rivals. The drug, which late-stage trials have shown helps people who have not responded to other multiple sclerosis treatments, has already been submitted for review by the European Medicines Agency. ...

Tags: Sanofi expects FDA decision on Lemtrada in H2,  Multiple Sclerosis Latest News